Form D · Biotechnology
Venn Biosciences Corp
South San Francisco, CA · CIK 0001756172
Offering snapshot reported Aug 18, 2021 · SEC filing
- Reported sold
- $173M Offering amount: $201M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 6, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 18, 2021 | Initial | $173,375,044 | No comparison | 14 | SEC filing |
| Sep 14, 2020 | Amendment | $33,689,885 | $2,000,000vs Jul 28, 2020 | 15 | SEC filing |
| Jul 28, 2020 | Initial | $31,689,885 | No comparison | 14 | SEC filing |
| Nov 8, 2019 | Amendment | $7,500,000 | $1,000,000vs Oct 17, 2018 | 10 | SEC filing |
| Oct 17, 2018 | Initial | $6,500,000 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-410506
Source: Form D, filed Aug 18, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Aldo Carrascoso | Director, Executive |
| Lieza Danan Leon | Director |
| Adam D'augelli | Director |
| Klaus Lindpaintner | Director |
| David Michael | Director |
| Jenny Rooke | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2 Tower Place, 5 Th Floor
South San Francisco, CA, 94080
South San Francisco, CA, 94080